OXURION announces its presence at the Paris SmallCap event on March 28, 2024.

OXURION announces its presence at the Paris SmallCapevent on March 28, 2024.

Leuven, BELGIUM - March 25, 2024 - 7:00 p.m, Oxurion NV (Euronext Brussels : OXUR), a Leuven-based biopharmaceutical company, is pleased to announce its participation in the SmallCap event, scheduled for March 28 in Paris.

The event, organized in key cities such as Paris, London, Frankfurt and Amsterdam, serves as a platform for bringing together European issuers and a wider network of institutional investors and family offices across Europe.

Pascal Ghoson, CEO of Oxurion, expresses his enthusiasm: "Our participation in this event is an opportunity. In fact. This will be an ideal place for us to unveil our future growth strategy and highlight the strengths that make us unique."

For more information on the event, please visit their website.

About Oxurion Oxurion

(Euronext Brussels: OXUR) is committed to the development of next-generation standard ophthalmic therapies for the treatment of retinal diseases. Oxurion's head office is in Leuven. Further information is available at www.oxurion.com.

Important information on forward-looking statements

Certain statements contained in this press release may be considered as “forward-looking". These forward looking statements are based on current expectations and are therefore subject to various risks and uncertainties. The company therefore cannot guarantee that these forward-looking statements will materialise and does not undertake to update or revise them, whether as a result of new information, future events or for any other reason. Additional information on the risks and uncertainties affecting the company and other factors that could cause actual results to differ materially from forward-looking statements is included in the company's annual report. This press release does not constitute an offer or an invitation to sell or buy securities or assets of Oxurion in any jurisdiction. No Oxurion securities may be offered or sold in the United States without registration under the 1933 U.S. Securities Act as amended, or pursuant to a waiver of such Act, and in accordance with all applicable state securities laws.

Contacts :

OXURION NVPascal [e-mail]

Attachments

• EN
• FR